{"id":"romosozumab-and-denosumab-cycle-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypocalcemia"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Romosozumab is a sclerostin inhibitor that promotes osteoblast activity and bone formation, while denosumab is a RANKL inhibitor that suppresses osteoclast-mediated bone resorption. The sequential or cyclic administration of these agents leverages their complementary mechanisms to achieve greater improvements in bone density and strength compared to monotherapy.","oneSentence":"Romosozumab and denosumab work sequentially to first stimulate bone formation and then inhibit bone resorption, increasing bone mineral density in osteoporosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:16.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT06938152","phase":"PHASE4","title":"Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-08","conditions":"Osteoporosis, Osteoporosis Postmenopausal","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cycle therapy group"],"phase":"marketed","status":"active","brandName":"Romosozumab and Denosumab Cycle Therapy","genericName":"Romosozumab and Denosumab Cycle Therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romosozumab and denosumab work sequentially to first stimulate bone formation and then inhibit bone resorption, increasing bone mineral density in osteoporosis. Used for Osteoporosis in postmenopausal women at high risk of fracture.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}